Boehringer Ingelheim Pharmaceuticals Inc. et al v. Cadila Healthcare Limited
| Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharmaceuticals Inc. and Boehringer Ingelheim International GmbH |
| Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited |
| 1:2019cv01295 |
| July 11, 2019 |
| US District Court for the District of Delaware |
| Colm F Connolly |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. § 271 |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on August 21, 2019. A more recent docket listing may be available from PACER.
| Document Text |
|---|
Filing 18
SO ORDERED, re (79 in 1:18-cv-01689-CFC-SRF, 12 in 1:19-cv-01295-CFC) Stipulation filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH. C.A. No. 19-1295 (CFC) shall be consolidated with C.A. No. 18-1689 (CFC)( consolidated) for all purposes, and all papers shall be filed in C.A. No. 18-1689 (CFC)( consolidated); Signed by Judge Colm F. Connolly on 8/21/2019. Associated Cases: 1:18-cv-01689-CFC-SRF, 1:19-cv-01295-CFC(fms)
|
| Case associated with lead case: Create association to 1:18-cv-01689-CFC-SRF. ALL PAPERS SHALL BE FILED in C.A. No. 18-1689 (CFC)( consolidated) (fms) |
| Filing 17 ANSWER to #6 Answer to Complaint, Counterclaim by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc..(Dellinger, Megan) |
| Filing 16 MOTION for Pro Hac Vice Appearance of Attorney Brett Garrison - filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Attachments: #1 Certification of Brett Garrison)(Bilson, David) |
| Pro Hac Vice Attorney Brett M. Garrison for Cadila Healthcare Limited and Zydus Pharmaceuticals (USA) Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (kmd) |
|
SO ORDERED, re #16 MOTION for Pro Hac Vice Appearance of Attorney Brett Garrison filed by Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Limited. Signed by Judge Colm F. Connolly on 8/16/2019. (fms)
|
|
SO ORDERED, re #15 STIPULATION TO EXTEND TIME for Plaintiffs to file their Answer to Defendants' Counterclaims (D.I. 6) to August 16, 2019 filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH. Signed by Judge Colm F. Connolly on 8/16/2019. (fms)
|
| Filing 15 STIPULATION TO EXTEND TIME for Plaintiffs to file their Answer to Defendants' Counterclaims (D.I. 6) to August 16, 2019 - filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc.. (Dellinger, Megan) |
| Filing 14 NOTICE OF SERVICE of (1) Zydus Pharmaceuticals (USA) Inc.'s and Cadila Healthcare Limited's Rule 26(a)(1) Initial Disclosures for C.A. No. 19-1295-CFC; and (2) Zydus Pharmaceuticals (USA) Inc.'s and Cadila Healthcare Limited's Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery for C.A. No. 19-1295-CFC filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Bilson, David) |
| Filing 13 NOTICE OF SERVICE of (1) Plaintiffs' Rule 26(a) Initial Disclosures and (2) Plaintiffs' Disclosures Under Paragraph 3 of the District of Delaware Default Standard for Discovery, Including Discovery of Electronically Stored Information (ESI) filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc..(Dellinger, Megan) |
| Filing 12 STIPULATION and Proposed Order Regarding Consolidation of Cases by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc.. (Dellinger, Megan) |
| Pro Hac Vice Attorney Ryan A. Cook, Chad A. Landmon, Jonathan M. Knowles, Edward M. Mathias for Zydus Pharmaceuticals (USA) Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (sam) |
| Filing 11 NOTICE OF SERVICE of Plaintiffs' Disclosures Pursuant to Paragraph 4(a) of the Default Standard For Discovery Including Discovery of Electronically Stored Information ("ESI") filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc..(Dellinger, Megan) |
|
Filing 10
ORDER, IT IS ORDERED that, on or before August 21, 2019, counsel for the parties shall confer regarding coordination of the cases and submit a proposed scheduling order to the Court or otherwise advise the Court that a separate scheduling conference is needed. ORDER, Setting Deadlines: Notice of Compliance deadline set for 8/21/2019. Signed by Judge Colm F. Connolly on 7/24/2019. (nmf)
|
| Filing 9 MOTION for Pro Hac Vice Appearance of Attorney Chad A. Landmon, Edward M. Mathias, Ryan A. Cook and Jonathan M. Knowles - filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Phillips, John) |
|
SO ORDERED, re #9 MOTION for Pro Hac Vice Appearance of Attorney Chad A. Landmon, Edward M. Mathias, Ryan A. Cook and Jonathan M. Knowles filed by Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Limited. Signed by Judge Colm F. Connolly on 7/23/2019. (fms)
|
| Filing 8 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Cadila Healthcare Limited for Zydus Pharmaceuticals (USA) Inc. filed by Zydus Pharmaceuticals (USA) Inc.. (Phillips, John) |
| Filing 7 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Cadila Healthcare Limited. (Phillips, John) |
| Filing 6 ANSWER to #1 Complaint, Affirmative Defenses, COUNTERCLAIM against All Plaintiffs by Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Limited.(Phillips, John) |
| Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb) |
| Summons Issued with Magistrate Consent Notice attached as to Cadila Healthcare Limited on 7/12/2019; Zydus Pharmaceuticals (USA) Inc. on 7/12/2019. Requesting party or attorney should pick up issued summons at the Help Desk, Room 4209, or call 302-573-6170 and ask the Clerk to mail the summons to them. (lak) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent C. H. Boehringer Sohn AG & Co. KG for Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc. filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc. (lak) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,579,449 B2 ;7,713,938 B2 ;8,551,957 B2 ;9,949,998 B2 ;10,258,637 B2. (lak) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 5/30/2019. Date of Expiration of Patent: See Attachment.Thirty Month Stay Deadline: 2/1/2022. (lak) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (lak) |
| Filing 1 COMPLAINT - filed against Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2683706.) - filed by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH. (Attachments: #1 Exhibit 1-5, #2 Civil Cover Sheet) (lak) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
